@NatRevDrugDisc profile picture
Nature Reviews Drug Discovery @NatRevDrugDisc

Editorial team of Nature Reviews Drug Discovery.

Joined April 2009
  • Tweets 4,092
  • Following 470
  • Followers 44,464
2,432 Photos and videos
For readers interested in the design of next-generation small-molecule kinase inhibitors, here's a comprehensive review nature.com/articles/s41573-0… rdcu.be/fn0n5
2
40
146
7,639
Upcoming FDA approval decisions in Q3 2026 nature.com/articles/d41573-0… Decisions on the US approval of new drugs include the kinase inhibitor zidesamtinib for non-small-cell lung cancer, which is being acquired by GSK in their $10.6 billion deal for Nuvalent this week
1
3
10
1,535
Antiviral peptide nabs FDA approval for hepatitis delta virus infection nature.com/articles/d41573-0… Gilead’s bulevirtide is the first treatment for the potentially fatal infection
2
13
22
2,166
The therapeutic potential of orphan adhesion G-protein-coupled receptors nature.com/articles/s41573-0… rdcu.be/fnAyg This Review in the June issue discusses disease roles of adhesion GPCRs, as well as strategies and compounds for therapeutically targeting them
1
21
70
4,035
Evolution of the psoriasis therapy landscape nature.com/articles/d41573-0… This new article analyses the pipeline of drugs for psoriasis and their market impact, highlighting the growing importance of oral therapies
1
9
32
7,598
For readers interested in next-generation GLP-1-based therapies for diabetes, obesity and more, here's a review nature.com/articles/s41573-0… rdcu.be/fnl3W
1
17
51
3,344
Nature Reviews Drug Discovery retweeted
STAT
@statnews
Jun 8
Eli Lilly has already established that its next-generation obesity drug can lead to highly rapid weight loss. Researchers disclosed new data that provide more details on the safety and tolerability of the closely-watched therapy. trib.al/ZbFlwbK

Lilly shares safety, tolerability data on its next-gen obesity drug

Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.

statnews.com
1
4
13
3,647
Analysis of a decade of post-authorisation studies for medicines approved by the EMA nature.com/articles/d41573-0… This article analyses studies that have been requested by the EMA in order to provide data on the quality, safety or efficacy of medicines after approval
5
21
1,754
For readers interested in synthetic lethality in cancer drug discovery, here's a review rdcu.be/fnaNw nature.com/articles/s41573-0…
16
61
3,985
Nature Reviews Drug Discovery retweeted
Matthew Herper
@matthewherper
Jun 8
Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate statnews.com/2026/06/08/panc… via @statnews

Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate

A combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an early-stage trial.

statnews.com
2
9
2,350
A guide to effective drug development through nonprofit models nature.com/articles/d41573-0… Patient organizations are reshaping rare disease drug development. Based on a survey, interviews and experience, this article discusses how to direct resources toward drug development goals
9
34
2,310
Our June issue is live! Read about the therapeutic potential of orphan GPCRs, wearable technologies in clinical trials for drug development, a renaissance in targeting the PI3K/AKT/mTOR pathway and more here nature.com/nrd/volumes/25/is…
1
8
26
1,987
Nature Reviews Drug Discovery retweeted
Nature Reviews Drug Discovery@NatRevDrugDisc
Jun 3
Towards mRNA therapeutics 2.0 nature.com/articles/s41573-0… This new Review discusses progress and insights from clinical studies on mRNA-based drugs, including enzyme replacement therapies, cancer immunotherapies, genome-modifying therapies and immune cell reprogramming therapies
55
141
11,289
Therapeutic and prophylactic strategies for Ebola caused by Bundibugyo virus nature.com/articles/d41573-0… This new article argues that the ongoing Ebola outbreak should be a turning point for moving R&D towards species-inclusive and broadly applicable filovirus countermeasures
6
14
1,747
Better data for better medicines: a path to data-driven medicines regulation nature.com/articles/d41573-0… This new Comment article highlights how the EU medicines regulatory system is becoming more data-driven @EMA_News
8
24
1,939
For readers interested in kinase inhibitors in cancer and beyond, this Review covers the expanding toolkit for kinase modulation, including allosteric modulators and proximity-inducing molecules such as molecular glues nature.com/articles/s41573-0… rdcu.be/fl5H5 #ASCO26
36
143
8,079
Nature Reviews Drug Discovery retweeted
Vivek Subbiah, MD
@VivekSubbiah
May 29
🚨⭐️Closing the paediatric gap in cancer drug development: a call to industry @NatRevDrugDisc @ASCO @oncodaily @OncoAlert @OpenMedicineHQ nature.com/articles/d41573-0…

Closing the paediatric gap in cancer drug development: a call to industry

Nature Reviews Drug Discovery - Despite transformative advances in adult oncology, children with cancer remain systematically underserved by drug development pipelines. We argue that sequential,...

nature.com
7
13
2,278
For readers interested in cancer immunotherapy, this article reviews the clinical landscape for agonistic antibodies as immunotherapies and discusses how mechanistic insights should broaden their clinical application nature.com/articles/s41573-0… rdcu.be/flSve #ASCO26
40
133
9,213
For readers interested in cyclin-dependent kinase inhibitors in cancer, here's a comprehensive review discussing their progression beyond CDK4/6 inhibitors for breast cancer nature.com/articles/s41573-0… rdcu.be/flRPL #ASCO26
16
49
3,527
Load more